Kroeger Christopher A. 4
4 · MapLight Therapeutics, Inc. · Filed May 11, 2026
Research Summary
AI-generated summary of this filing
MapLight Therapeutics (MPLT) CEO Christopher Kroeger Sells 68,491 Shares
What Happened
Christopher A. Kroeger, CEO of MapLight Therapeutics (MPLT), reported multiple open‑market sales totaling 68,491 shares between May 7 and May 11, 2026, for aggregate proceeds of approximately $1,949,635. Major lots included 29,624 shares on May 8 ($814,068), 14,880 shares on May 7 ($423,634), and 6,871 shares on May 11 (~$206,405). All reported dispositions are sales (S) — routine sales reduce holdings rather than a purchase that would signal added insider exposure.
Key Details
- Transaction dates: May 7, May 8 and May 11, 2026.
- Reported per‑lot (examples): 14,880 @ $28.47 ($423,634); 29,624 @ $27.48 ($814,068); 6,871 @ $30.04 ($206,405); other lots at prices between ~$27.48 and $30.56 (filing reports weighted averages; footnotes show more detailed price ranges).
- Total shares sold: 68,491. Total proceeds: ≈ $1,949,635.
- Shares held after transaction: Not specified in the material provided in this summary (check the Form 4 for Column 9 balance).
- Notable footnotes: At least some sales were made pursuant to a Rule 10b5‑1 trading plan adopted Dec 29, 2025 (F1). Several entries report weighted‑average prices and disclose that the shares were sold in multiple trades at ranges (see footnotes F2–F10). F11 notes shares are held by the C&M Kroeger Nominee Trust, of which the reporting person is co‑trustee with voting and dispositive power.
- Filing timeliness: Form filed May 11, 2026 — covering trades through May 11 — appears timely under standard Form 4 reporting rules (no late‑filing flag was indicated).
Context
- Sales under a Rule 10b5‑1 plan are pre‑arranged and are often used to systematically sell shares; such sales are not, by themselves, proof of a change in the insider’s view of the company.
- For retail investors, purchases by insiders tend to carry more weight as a bullish signal; disclosed sales may be for diversification, tax, or personal-liquidity reasons.
- The filing includes weighted‑average prices and offers to provide per‑trade price breakdowns on request (per footnotes), so review the full Form 4 if you need transaction‑by‑transaction pricing or the post‑transaction holding balance.
Insider Transaction Report
Form 4
Kroeger Christopher A.
DirectorChief Executive Officer
Transactions
- Sale
Voting Common Stock
[F1][F2]2026-05-07$28.47/sh−14,880$423,634→ 1,565,940 total - Sale
Voting Common Stock
[F1][F3]2026-05-07$29.15/sh−5,220$152,163→ 1,560,720 total - Sale
Voting Common Stock
[F1][F4]2026-05-08$27.48/sh−29,624$814,068→ 1,531,096 total - Sale
Voting Common Stock
[F1][F5]2026-05-08$28.56/sh−1,582$45,182→ 1,529,514 total - Sale
Voting Common Stock
[F1][F6]2026-05-08$29.20/sh−3,205$93,586→ 1,526,309 total - Sale
Voting Common Stock
[F1][F7]2026-05-11$27.57/sh−342$9,429→ 1,525,967 total - Sale
Voting Common Stock
[F1][F8]2026-05-11$28.70/sh−877$25,170→ 1,525,090 total - Sale
Voting Common Stock
[F1][F9]2026-05-11$30.04/sh−6,871$206,405→ 1,518,219 total - Sale
Voting Common Stock
[F1][F10]2026-05-11$30.56/sh−5,890$179,998→ 1,512,329 total
Holdings
- 101,190(indirect: See footnote)
Voting Common Stock
[F11]
Footnotes (11)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.885 to $28.8833 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.91 to $29.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $28.1099 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.11 to $29.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.12 to $29.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.3045 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Kristopher L. Hanson, Attorney-in-Fact|2026-05-11